Health and Fitness Health and Fitness
Wed, February 2, 2011
Tue, February 1, 2011
[ Tue, Feb 01st 2011 ] - Market Wire
Gerald Rosenfeld Rejoins Lazard
[ Tue, Feb 01st 2011 ] - Market Wire
Broadridge Declares Dividend

ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 25, 2011


Published on 2011-02-01 12:06:00 - Market Wire
  Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc. ] (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, invites investors, journalists and the general public to listen to a live webcast of the Companya™s investment community meeting on February 25, 2011. The webcast will begin at 8:30 a.m. ET and may be accessed through the Investor Information section of the Companya™s website, [ www.immunogen.com ]. The meeting is expected to last approximately three hours, including a short break. An archive of the webcast will be available on the Companya™s website through March 11, 2011.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently seven TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGena™s collaborative partners include Amgen, Bayer Schering Pharma, Biogen Idec, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at [ www.immunogen.com ].